R1 RCM (RCM) Lowered to “Sell” at BidaskClub

Share on StockTwits

BidaskClub lowered shares of R1 RCM (NASDAQ:RCM) from a hold rating to a sell rating in a research report sent to investors on Saturday morning.

RCM has been the subject of a number of other reports. Zacks Investment Research downgraded shares of R1 RCM from a hold rating to a sell rating in a report on Friday, November 16th. Citigroup assumed coverage on shares of R1 RCM in a report on Monday, December 10th. They issued a buy rating and a $20.00 price target for the company. Two equities research analysts have rated the stock with a sell rating, one has given a hold rating, four have assigned a buy rating and one has given a strong buy rating to the company’s stock. The stock presently has a consensus rating of Buy and a consensus target price of $12.54.

RCM stock traded up $0.15 during trading hours on Friday, hitting $8.31. The company’s stock had a trading volume of 663,515 shares, compared to its average volume of 827,261. The company has a debt-to-equity ratio of 37.41, a current ratio of 1.06 and a quick ratio of 1.06. R1 RCM has a 12 month low of $4.20 and a 12 month high of $11.00.

R1 RCM (NASDAQ:RCM) last posted its quarterly earnings data on Wednesday, November 7th. The financial services provider reported ($0.17) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.05) by ($0.12). The firm had revenue of $250.40 million for the quarter, compared to the consensus estimate of $240.09 million. R1 RCM had a negative return on equity of 132.32% and a negative net margin of 10.70%. R1 RCM’s quarterly revenue was up 103.2% on a year-over-year basis. During the same period in the prior year, the company posted ($0.08) earnings per share. Research analysts anticipate that R1 RCM will post -0.18 EPS for the current year.

In other news, Director Charles J. Ditkoff sold 20,635 shares of the stock in a transaction on Friday, November 16th. The shares were sold at an average price of $8.47, for a total value of $174,778.45. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. 59.40% of the stock is owned by corporate insiders.

Hedge funds have recently made changes to their positions in the company. GSA Capital Partners LLP acquired a new stake in shares of R1 RCM during the 2nd quarter worth about $122,000. Oppenheimer Asset Management Inc. acquired a new stake in shares of R1 RCM during the 3rd quarter worth about $126,000. WINTON GROUP Ltd acquired a new stake in shares of R1 RCM during the 3rd quarter worth about $139,000. Cubist Systematic Strategies LLC increased its position in shares of R1 RCM by 49.5% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 20,946 shares of the financial services provider’s stock worth $182,000 after purchasing an additional 6,938 shares in the last quarter. Finally, Jane Street Group LLC acquired a new stake in shares of R1 RCM during the 2nd quarter worth about $190,000. Institutional investors own 57.42% of the company’s stock.

About R1 RCM

R1 RCM Inc provides revenue cycle management (RCM) for healthcare providers in the United States. It offers end-to-end RCM services to manage their revenue cycle operations, which encompass patient registration, insurance and benefit verification, medical treatment documentation and coding, and bill preparation and collection from patients and payers.

Further Reading: Debt-To-Equity Ratio

Analyst Recommendations for R1 RCM (NASDAQ:RCM)

Receive News & Ratings for R1 RCM Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for R1 RCM and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Jonathan Corr Sells 12,515 Shares of Ellie Mae Inc  Stock
Jonathan Corr Sells 12,515 Shares of Ellie Mae Inc Stock
T-Mobile Us Inc  Insider Thomas Christopher Keys Sells 43,000 Shares
T-Mobile Us Inc Insider Thomas Christopher Keys Sells 43,000 Shares
Astrotech  Shares Up 6.5%
Astrotech Shares Up 6.5%
Teekay Offshore Partners  Trading 5.2% Higher
Teekay Offshore Partners Trading 5.2% Higher
Workiva  Issues Q1 2019 Earnings Guidance
Workiva Issues Q1 2019 Earnings Guidance
Autolus Therapeutics Ltd –  Receives $44.00 Consensus PT from Analysts
Autolus Therapeutics Ltd – Receives $44.00 Consensus PT from Analysts


© 2006-2019 Ticker Report